RT Journal Article
SR Electronic
T1 Orthostatic Hypotension In Parkinson Disease: What Is New?
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP 10.1212/CPJ.0000000000200068
DO 10.1212/CPJ.0000000000200068
A1 Guillaume Lamotte
A1 Abhishek Lenka
YR 2022
UL http://cp.neurology.org/content/early/2022/08/24/CPJ.0000000000200068.abstract
AB Purpose of the review: Orthostatic hypotension (OH) is the primary manifestation of cardiovascular autonomic dysfunction in Parkinson’s disease (PD) and can be a prodromal feature of the disease. We review the recent progress in the field of autonomic dysfunction in PD.Recent findings: Individuals with isolated neurogenic OH should be followed up frequently as they may evolve into PD, dementia with Lewy bodies, or multiple system atrophy. The prevalence of OH in PD increases with disease stages but the role of levodopa remains unclear. Measurement of supine and standing heart rate and blood pressure allows for accurate identification of neurogenic OH in the clinic.Summary: Accurate identification of neurogenic OH in the clinic is crucial for identification of individuals who may benefit from participation in neuroprotective trials in the future. The treatment of OH in PD should be individualized and may reduce the risk of falls, cognitive impairment, and death.